Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

Impurities in generic pharmaceutical development.

Kovaleski J, Kraut B, Mattiuz A, Giangiulio M, Brobst G, Cagno W, Kulkarni P, Rauch T.

Adv Drug Deliv Rev. 2007 Jan 10;59(1):56-63. Epub 2006 Nov 15. Review.

PMID:
17196702
2.

Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.

Maddineni J, Walenga JM, Jeske WP, Hoppensteadt DA, Fareed J, Wahi R, Bick RL.

Clin Appl Thromb Hemost. 2006 Jul;12(3):267-76.

PMID:
16959680
3.

Bioequivalence and other unresolved issues in generic drug substitution.

Meredith P.

Clin Ther. 2003 Nov;25(11):2875-90.

PMID:
14693311
4.
5.

Polymorphism in generic drug product development.

Snider DA, Addicks W, Owens W.

Adv Drug Deliv Rev. 2004 Feb 23;56(3):391-5. Review.

PMID:
14962588
6.

Pharmaceutical quality of generic isotretinoin products, compared with Roaccutane.

Taylor PW, Keenan MH.

Curr Med Res Opin. 2006 Mar;22(3):603-15.

PMID:
16574043
7.

Pharmaceutical impurities: regulatory perspective for Abbreviated New Drug Applications.

Basak AK, Raw AS, Al Hakim AH, Furness S, Samaan NI, Gill DS, Patel HB, Powers RF, Yu L.

Adv Drug Deliv Rev. 2007 Jan 10;59(1):64-72. Epub 2006 Nov 15. Review.

PMID:
17196703
8.

[Generic drugs: we must cut pharmaceutical spending but undertaking drug quality].

Carrillo Norte JA, Postigo Mota S.

Rev Enferm. 2012 Feb;35(2):10-9. Spanish.

PMID:
22670381
9.

Current approaches to the use of generic antiepileptic drugs.

Krämer G, Biraben A, Carreno M, Guekht A, de Haan GJ, Jedrzejczak J, Josephs D, van Rijckevorsel K, Zaccara G.

Epilepsy Behav. 2007 Aug;11(1):46-52. Epub 2007 May 29. Review.

PMID:
17537678
10.

Current status of the international comparator (reference) product system.

Idänpään-Heikkilä JE.

Eur J Drug Metab Pharmacokinet. 2000 Jan-Mar;25(1):36-7.

PMID:
11032088
11.
12.

Pharmaceutical quality of nine generic orlistat products compared with Xenical(r).

Taylor PW, Arnet I, Fischer A, Simpson IN.

Obes Facts. 2010 Aug;3(4):231-7. doi: 10.1159/000319450. Epub 2010 Aug 9.

13.

The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence.

Duh MS, Cahill KE, Paradis PE, Cremieux PY, Greenberg PE.

Expert Opin Pharmacother. 2009 Oct;10(14):2317-28. doi: 10.1517/14656560903140525. Review.

PMID:
19663636
14.

Analysis of purity profiles of generic lisinopril tablets marketed in Croatia.

Benković G, Sokolić M, Cudina B, Zulj RT, Tomić S.

Coll Antropol. 2013 Jun;37(2):601-6.

PMID:
23941010
15.

[Generics: similarities, bioequivalence but no conformity].

Even-Adin D, De Muylder JA, Sternon J.

J Pharm Belg. 2002 Jan-Feb;57(1):14-20. Review. French.

PMID:
11913095
16.

[Generics: essentially similar, bioequivalent but not identical].

Even-Adin D, De Muylder JA, Sternon J.

Rev Med Brux. 2001 Dec;22(6):513-20. Review. French.

PMID:
11811047
17.

[Generics: authorization to market and quality guarantees].

De Muylder JA.

Rev Med Brux. 2000 Sep;21(4):A276-8. French.

PMID:
11068480
18.

The importance of brand continuity in epilepsy drugs.

Goodwin M.

Nurs Times. 2005 Jun 21-27;101(25):26-7. Review.

PMID:
15997944
19.

[Sevoflurane and propofol: original and generic].

Al-Nasser B.

Ann Fr Anesth Reanim. 2008 Jan;27(1):120-2. doi: 10.1016/j.annfar.2007.11.010. Epub 2008 Jan 8. Review. French. No abstract available.

PMID:
18191934

Supplemental Content

Support Center